Abstract
The MERIT study was a single-arm, phase II clinical trial of nivolumab for the second- or third-line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 5438-5440 |
| Number of pages | 3 |
| Journal | Clinical Cancer Research |
| Volume | 25 |
| Issue number | 18 |
| DOIs | |
| State | Published - Sep 15 2019 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint Dive into the research topics of 'Nivo-lution in mesothelioma'. Together they form a unique fingerprint.
Cite this
Mansfield, A. S., & Zauderer, M. G. (2019). Nivo-lution in mesothelioma. Clinical Cancer Research, 25(18), 5438-5440. https://doi.org/10.1158/1078-0432.CCR-19-1836